Karyopharm Therapeutics
KPTI
137 hedge funds and large institutions have $145M invested in Karyopharm Therapeutics in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 22 closing their positions.
153% more call options, than puts
Call options by funds: $613K | Put options by funds: $242K
36% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 22
6% more funds holding
Funds holding: 129 → 137 (+8)
5% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 41
0.38% less ownership
Funds ownership: 5.15% → 4.77% (-0.38%)
57% less capital invested
Capital invested by funds: $340M → $145M (-$195M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.08M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$6.84M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.09M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.39M |
| 5 |
Millennium Management
New York
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$22.9M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$10.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.23M |
| 4 |
Barclays
London,
United Kingdom
|
-$5M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Allspring Global Investments
Charlotte,
North Carolina
| – | -$95.7K | -1,640 | Closed |
|
|
ATPW
152
Ashton Thomas Private Wealth
Scottsdale,
Arizona
| – | -$62.2K | -1,067 | Closed |
|
153
Squarepoint
New York
| – | -$48.8K | -837 | Closed |
|
|
MC
154
Moors & Cabot
Boston,
Massachusetts
| – | -$47.5K | -813 | Closed |
|
|
BCM
155
Bayesian Capital Management
Brooklyn,
New York
| – | -$46.2K | -792 | Closed |
|
|
BAM
156
Belpointe Asset Management
Reno,
Nevada
| – | -$3.89K | -67 | Closed |
|
|
ASN
157
Advisory Services Network
Atlanta,
Georgia
| – | -$2.33K | -40 | Closed |
|
|
LC
158
Lindbrook Capital
Calabasas,
California
| – | -$1.55K | -27 | Closed |
|
|
QC
159
Quent Capital
New York
| – | -$1.5K | -26 | Closed |
|
KPTI Hedge Fund Activity: Q2 2023 in Review
137 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2023, worth a combined $145M — down 57% from $340M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new KPTI positions and 22 closed out — a net gain of 8 holders — while 43 added to existing stakes and 41 trimmed.
The largest buyer was BlackRock, adding an estimated $7.08M. The largest seller was State Street, cutting an estimated $22.9M.
- 137 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2023, up from 129 in Q1 2023.
- Funds reported $145M of Karyopharm Therapeutics stock for Q2 2023, down 57% quarter-over-quarter.
- 30 funds opened new Karyopharm Therapeutics positions in Q2 2023 and 22 closed out, a net change of +8 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2023 was BlackRock, an estimated $7.08M added.
- The largest Karyopharm Therapeutics seller in Q2 2023 was State Street, an estimated $22.9M sold.
Based on aggregated 13F filings for Q2 2023.